Edwin DeJesus

Summary

Publications

  1. doi request reprint Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL 32803, USA
    J Acquir Immune Defic Syndr 51:163-74. 2009
  2. pmc A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
    Princy N Kumar
    Georgetown University Medical Center, Washington, DC, USA
    AIDS Res Ther 6:3. 2009
  3. doi request reprint Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    Antivir Ther 15:711-20. 2010
  4. ncbi request reprint Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, Florida
    J Int Assoc Physicians AIDS Care (Chic) 6:95-100. 2007
  5. pmc Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study
    Edwin DeJesus
    Orlando Immunology Center, 1701 N Mills Avenue, Orlando, FL 32803, USA
    Antimicrob Agents Chemother 52:4315-9. 2008
  6. doi request reprint A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients
    E Dejesus
    Orlando Immunology Center, Orlando, FL 32803, USA
    Int J Clin Pract 65:1240-9. 2011
  7. doi request reprint Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine
    Edwin DeJesus
    Orlando Immunology Center, Orlando, Florida 32803, USA
    HIV Clin Trials 9:103-14. 2008
  8. doi request reprint Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
    Roberto Ortiz
    Orlando Immunology Center, Orlando, Florida, USA
    AIDS 22:1389-97. 2008
  9. doi request reprint Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    Lancet 379:2429-38. 2012
  10. pmc Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects
    Edwin DeJesus
    Orlando Immunology Center, Florida, USA
    Antimicrob Agents Chemother 50:3157-9. 2006

Detail Information

Publications14

  1. doi request reprint Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL 32803, USA
    J Acquir Immune Defic Syndr 51:163-74. 2009
    ....
  2. pmc A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
    Princy N Kumar
    Georgetown University Medical Center, Washington, DC, USA
    AIDS Res Ther 6:3. 2009
    ..Both regimens offer benefits in select therapy-naïve subjects. TRIAL REGISTRATION: [Clinical Trials Identifier, NCT00082394]...
  3. doi request reprint Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    Antivir Ther 15:711-20. 2010
    ..A pharmacokinetic trial was conducted to evaluate the potential for once-daily etravirine in antiretroviral regimens without and with darunavir/ritonavir...
  4. ncbi request reprint Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, Florida
    J Int Assoc Physicians AIDS Care (Chic) 6:95-100. 2007
    ..Objective: To determine whether dronabinol affects appetite and weight status in patients living with HIV/AIDS...
  5. pmc Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study
    Edwin DeJesus
    Orlando Immunology Center, 1701 N Mills Avenue, Orlando, FL 32803, USA
    Antimicrob Agents Chemother 52:4315-9. 2008
    ....
  6. doi request reprint A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients
    E Dejesus
    Orlando Immunology Center, Orlando, FL 32803, USA
    Int J Clin Pract 65:1240-9. 2011
    ..NEWART was designed to support and confirm results from ARTEN, an international trial with similar design and study endpoints...
  7. doi request reprint Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine
    Edwin DeJesus
    Orlando Immunology Center, Orlando, Florida 32803, USA
    HIV Clin Trials 9:103-14. 2008
    ....
  8. doi request reprint Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
    Roberto Ortiz
    Orlando Immunology Center, Orlando, Florida, USA
    AIDS 22:1389-97. 2008
    ....
  9. doi request reprint Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    Lancet 379:2429-38. 2012
    ..We compared EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection...
  10. pmc Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects
    Edwin DeJesus
    Orlando Immunology Center, Florida, USA
    Antimicrob Agents Chemother 50:3157-9. 2006
    ..A regimen of 700 mg of FPV BID plus 100 mg of RTV BID may be coadministered with NVP without dose adjustment...
  11. doi request reprint Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK
    Edwin DeJesus
    Orlando Immunology Center, Orlando, Florida, USA
    HIV Clin Trials 13:228-32. 2012
    ..Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration compared with efavirenz irrespective of baseline demographic and prognostic factors, including in patients with high viral loads...
  12. ncbi request reprint Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial
    Edwin DeJesus
    IDC Research Initiative, Altamonte Springs, FL, USA
    Clin Infect Dis 39:411-8. 2004
    ..Median increase above baseline in CD4(+) cell count was similar (q.d. group, +144 cells/mm(3); b.i.d. group, +146 cells/mm(3)), and the incidences of adverse events, disease progression, and HIV-associated conditions were comparable...
  13. ncbi request reprint Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    J Acquir Immune Defic Syndr 43:1-5. 2006
    ..GS-9137 is a potent low-nanomolar strand transfer inhibitor of HIV-1 integrase...
  14. pmc Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
    David A Cooper
    aKirby Institute, University of New South Wales, Sydney, Australia bPfizer Inc, Groton, Connecticut, USA cUniversity of Witwatersrand, Johannesburg dPrivate Practice, Pretoria, South Africa eOrlando Immunology Center, Orlando, Florida, USA fSaint Pierre University Hospital, Brussels, Belgium gUniversity of Toronto, Toronto, Canada hSan Raffaele Scientific Institute, Milan, Italy iPfizer Inc, New York jUniversity of Alabama at Birmingham, Birmingham, Alabama, USA kPfizer Global Research and Development, Sandwich, UK
    AIDS 28:717-25. 2014
    ..Efavirenz Regimens as Initial Therapy (MERIT) study. Here we report 5-year findings...